<DOC>
	<DOC>NCT00736775</DOC>
	<brief_summary>This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study that will be conducted in the United States and consists of a single ascending-dose stage followed by a multidose, parallel-treatment stage. This study will be conducted in approximately 50 adult patients between 50-85 years old who have mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable AD according to the NINCDSADRDA Criteria Approved AD treatments (AchE inhibitors+/memantine) must be stable for ≥ 3 months prior to screening Other prescription medications must be stable for ≥ 1 month prior to screening Female patients with reproductive potential History or presence of any clinically significant CNS disease History of treatment with any protein therapeutic targeting Abeta</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>AD</keyword>
	<keyword>Alzheimer's</keyword>
	<keyword>Alzheimers</keyword>
</DOC>